Anti-inflammatory IL-8 Regulation via an Advanced Drug Delivery System at the Oral Mucosa.
ACS Appl Bio Mater
; 6(6): 2145-2157, 2023 06 19.
Article
en En
| MEDLINE
| ID: mdl-37216981
ABSTRACT
Oral inflammatory diseases are highly prevalent in the worldwide population. Topical treatment of inflammation is challenging due to dilution effects of saliva and crevicular fluid. Thus, there is a great medical need to develop smart anti-inflammatory drug delivery systems for mucosa treatment. We compared two promising anti-inflammatory dendritic poly(glycerol-caprolactone) sulfate (dPGS-PCL) polymers for their applicability to the oral mucosa. Using an ex vivo porcine tissue model, cell monolayers, and full-thickness 3D oral mucosal organoids, the polymers were evaluated for muco-adhesion, penetration, and anti-inflammatory properties. The biodegradable dPGS-PCL97 polymers adhered to and penetrated the masticatory mucosa within seconds. No effects on metabolic activity and cell proliferation were found. dPGS-PCL97 revealed a significant downregulation of pro-inflammatory cytokines with a clear preference for IL-8 in cell monolayers and mucosal organoids. Thus, dPGS-PCL97 exhibits excellent properties for topical anti-inflammatory therapy, suggesting new therapeutic avenues in the treatment of oral inflammatory diseases.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Interleucina-8
/
Mucosa Bucal
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
ACS Appl Bio Mater
Año:
2023
Tipo del documento:
Article
País de afiliación:
Alemania